Effect of NNRTI or INSTI on Nonalcoholic Steatosis in HIV/AIDS Patients

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Identifying patients at risk of NAFLD(Nonalcoholic fatty liver disease), especially severe disease with NASH(nonalcoholic steatohepatitis) and fibrosis, is critical. Prevalence of NAFLD in PLWH(People Living With HIV) evaluated by different imaging techniques including US (ultrasonography), elastography, CT(computed tomography ), and magnetic resonance varies from 13% to 58.6% in all published studies. In previous studies, the effect of ART(Anti-Retroviral Therapy) on NAFLD was limited. A cross-sectional analysis found that INSTI(Integrase strand transfer inhibitor) was associated with a higher prevalence of steatosis in AIDS (acquired immunodeficiency syndrome) patients. However, it is not clear whether there is a difference in the degree of nonalcoholic steatosis between AIDS patients receiving NNRTI(non-nucleoside reverse transcriptase inhibitors). Therefore, the investigators plan to conduct a prospective study to assess whether there is any difference in the degree of nonalcoholic steatosis and fibrosis between Chinese HIV(human immunodeficiency virus)/AIDS patients after initial treatment with NNRTI or INSTI, or switching from NNRTI to INSTI.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Newly treated or treated AIDS patients;

• Regular follow-up visits to the hospital, medication compliance is good;

• Patients or their family members were willing to participate in the study by understanding the study plan and providing written informed consent.

Locations
Other Locations
China
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
QING ZHANG
zhangqingpumch@163.com
15001278131
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 200
Sponsors
Collaborators: Wuxi Hisky Medical Technology Co Ltd
Leads: Peking Union Medical College Hospital

This content was sourced from clinicaltrials.gov